Literature DB >> 2590384

Sex-steroid receptors in the diethylnitrosamine model of hepatocarcinogenesis: modifications by gonadal ablation and steroid replacement therapy.

S Tejura1, G R Rodgers, M H Dunion, M A Parsons, J C Underwood, P M Ingleton.   

Abstract

The results of this study confirm our previous report of increased androgen receptor expression in livers of female SUAH Wistar rats during development of liver tumours induced by diethylnitrosamine (DENA). In adult female rats not treated with DENA, removal of the ovary increased liver androgen receptor levels but testosterone did not further enhance the androgen receptor status of ovariectomized rats. In normal adult males the testis and/or testosterone maintained high levels of androgen receptors but oestrogen reduced them in castrated rats. Oestrogen receptor levels were not significantly changed in either males or females by gonadectomy. Treatment of female rats with DENA for 10 and 16 weeks increased liver androgen receptors but oestrogen receptors were only reduced by 16 weeks of DENA treatment, whether the rats were intact or ovariectomized. Concentrations of liver androgen receptors were increased in intact and castrated male rats by 10 and 16 weeks of DENA treatment, an increase not seen in the previous experiments. Oestrogen appeared to inhibit both the increases in liver androgen receptor expression and liver tumour development in rats treated with the weakly carcinogenic dose of 10 weeks of DENA. However, the full carcinogenic dose of 16 weeks of DENA increased liver androgen receptors and decreased oestrogen receptors in female rats regardless of sex-steroid status. Development of malignant hepatocellular carcinoma (HCC) was associated with both an increase in liver androgen receptors and a decrease in oestrogen receptors. Maintenance of relatively high levels of liver oestrogen receptors appeared to protect the liver against development of HCC.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2590384     DOI: 10.1677/jme.0.0030229

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  9 in total

1.  Hepatic androgen receptor suppresses hepatocellular carcinoma metastasis through modulation of cell migration and anoikis.

Authors:  Wen-Lung Ma; Cheng-Lung Hsu; Chun-Chieh Yeh; Ming-Heng Wu; Chiung-Kuei Huang; Long-Bin Jeng; Yao-Ching Hung; Tze-Yi Lin; Shuyuan Yeh; Chawnshang Chang
Journal:  Hepatology       Date:  2012-06-05       Impact factor: 17.425

2.  Dehydroepiandrosterone-induces miR-21 transcription in HepG2 cells through estrogen receptor β and androgen receptor.

Authors:  Yun Teng; Lacey M Litchfield; Margarita M Ivanova; Russell A Prough; Barbara J Clark; Carolyn M Klinge
Journal:  Mol Cell Endocrinol       Date:  2014-05-17       Impact factor: 4.102

3.  Activation of androgen receptor induces ID1 and promotes hepatocellular carcinoma cell migration and invasion.

Authors:  Junping Ao; Jiao Meng; Lei Zhu; Huizhen Nie; Chenchen Yang; Jinjun Li; Jianren Gu; Qiushi Lin; Weiwen Long; Xiaoqun Dong; Chao Li
Journal:  Mol Oncol       Date:  2012-07-05       Impact factor: 6.603

Review 4.  Androgen receptor roles in hepatocellular carcinoma, fatty liver, cirrhosis and hepatitis.

Authors:  Wen-Lung Ma; Hsueh-Chou Lai; Shuyuan Yeh; Xiujun Cai; Chawnshang Chang
Journal:  Endocr Relat Cancer       Date:  2014-05-06       Impact factor: 5.678

Review 5.  Role of sex steroid receptors in pathobiology of hepatocellular carcinoma.

Authors:  Mamta Kalra; Jary Mayes; Senait Assefa; Anil-K Kaul; Rashmi Kaul
Journal:  World J Gastroenterol       Date:  2008-10-21       Impact factor: 5.742

6.  Androgen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma.

Authors:  Wen-Lung Ma; Cheng-Lung Ma; Cheng-Lung Hsu; Ming-Heng Wu; Chun-Te Wu; Cheng-Chia Wu; Jiann-Jyh Lai; Yuh-Shan Jou; Chun-Wei Chen; Shuyuan Yeh; Chawnshang Chang
Journal:  Gastroenterology       Date:  2008-05-22       Impact factor: 22.682

7.  Reproductive factors, exogenous hormone use and risk of hepatocellular carcinoma among US women: results from the Liver Cancer Pooling Project.

Authors:  K A McGlynn; V V Sahasrabuddhe; P T Campbell; B I Graubard; J Chen; L M Schwartz; J L Petrick; M C Alavanja; G Andreotti; D A Boggs; J E Buring; A T Chan; N D Freedman; S M Gapstur; A R Hollenbeck; L Hou; L Y King; J Koshiol; M Linet; J R Palmer; J N Poynter; M Purdue; K Robien; C Schairer; H D Sesso; A Sigurdson; J Wactawski-Wende; A Zeleniuch-Jacquotte
Journal:  Br J Cancer       Date:  2015-03-31       Impact factor: 7.640

Review 8.  Nonalcoholic steatohepatitis-related hepatocellular carcinoma: is there a role for the androgen receptor pathway?

Authors:  Mahmoud A Ali; Sahin Lacin; Reham Abdel-Wahab; Mark Uemura; Manal Hassan; Asif Rashid; Dan G Duda; Ahmed O Kaseb
Journal:  Onco Targets Ther       Date:  2017-03-03       Impact factor: 4.147

9.  Hormone replacement therapy is associated with reduced hepatocellular carcinoma risk and improved survival in postmenopausal women with hepatitis B: A nationwide long-term population-based cohort study.

Authors:  Chun-Hsiang Wang; Ruey-Chang Lin; Hua-Yin Hsu; Yuan-Tsung Tseng
Journal:  PLoS One       Date:  2022-07-21       Impact factor: 3.752

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.